论文部分内容阅读
目的评价腹腔免疫化疗对侵及浆膜的进行期胃癌根治术后预防腹腔复发的疗效。方法１９９２年１０月至１９９４年１２月对１９９例可切除的进行期胃癌病人随机分成治疗组和对照组。治疗组１０４例应用卡铂２００ｍｇ＋白介素Ⅱ２０～４０万单位加入生理盐水２００～３００ｍｌ进行多点腹腔穿刺注射，连用５周，４个月后重复。对照组９５例则常规给予优福定口服。结果治疗组和对照组３年生存率分别为６０６％、４５３％（Ｐ＜００１）。腹腔复发率分别为４８％、３４９％（Ｐ＜００１）。结论腹腔免疫化疗可预防侵犯浆膜的进展期胃癌术后腹腔复发，是一种方法简便，安全可行，副作用少，可重复应用的有效治疗手段
Objective To evaluate the efficacy of intraperitoneal immunotherapy for the prevention of intraperitoneal recurrence after radical resection of serosa invasive gastric cancer. Methods From October 1992 to December 1994, 199 resectable patients with advanced gastric cancer were randomly divided into treatment and control groups. In the treatment group, 104 cases of carboplatin 200mg + interleukin II 200-300,000 units were added with normal saline 200-300ml for multi-point intraperitoneal puncture injection, which was repeated for 5 weeks and 4 months later. In the control group, 95 patients were routinely given yufuding orally. Results The three-year survival rates of the treatment and control groups were 60.6% and 45.4%, respectively (P<0. 01). The recurrence rate in the abdominal cavity was 4.8% and 34.9%, respectively (P<0. 01). Conclusion Intraperitoneal immunochemotherapy can prevent postoperative abdominal cavity recurrence after advanced gastric cancer invading the serous membrane. It is a simple, safe and feasible method with few side effects and can be used repeatedly as an effective treatment method.